On the other hand, despite the high sensitivity (85%) and specificity (98%) of PSMA-PET/CT [14], other processes may also overexpress PSMA, probably related to the presence of PSMA expression in the endothelial cell membrane of neovessels: for example benign lesions such as Paget bone disease, vertebral hemangioma, or fibrous dysplasia [46]; and malignant lesions such as kidney cancer, breast cancer, or sarcomas [47]. Here, FOLH1 is linked to breast cancer.